Despite its intensive investigation for almost two decades, c-Myc remains a fascinating and enigmatic subject. A large and compelling body of evidence indicates that c-Myc is a transcription factor with central roles in the regulation of cell proliferation, dierentiation, and apoptosis, but its exact function has remained elusive. In this review we survey recent advances in the identi®cation and analysis of c-Mycbinding proteins, which suggest insights into the transcriptional roles of c-Myc but which also extend the existing functional paradigms. The C-terminal domain (CTD) of c-Myc mediates interaction with Max and physiological recognition of DNA target sequences, events needed for all biological actions. Recently described interactions between the CTD and other cellular proteins, including YY-1, AP-2, BRCA-1, TFII-I, and Miz-1, suggest levels of regulatory complexity beyond Max in controlling DNA recognition by cMyc. The N-terminal domain (NTD), which includes the evolutionarily conserved and functionally crucial Myc Box sequences (MB1 and MB2), contains the transcription activation domain (TAD) of c-Myc as well as regions required for transcriptional repression, cell cycle regulation, transformation, and apoptosis. In addition to interaction with the retinoblastoma family protein p107, the NTD has been shown to interact with a-tubulin and the novel adaptor proteins Bin1, MM-1, Pam, TRRAP, and AMY-1. The structure of these proteins and their eects on c-Myc actions suggest links to the transcriptional regulatory machinery as well as to cell cycle regulation, chromatin modeling, and apoptosis. Investigations of this emerging NTD-based network may reveal how c-Myc is regulated and how it aects cell fate, as well as providing tools to distinguish the physiological roles of various Myc target genes.
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Keywords: neoplastic transformation; apoptosis; transcription; oncogene; tumor suppressor; proliferation The Myc family of nuclear oncoproteins are key cell growth regulators that are oncogenically activated in a large fraction of human malignancies (reviewed in Cole, 1986; Kelly and Siebenlist, 1986; Spencer and Groudine, 1991) . Most investigations have focused on the product of the c-Myc gene, which is widely expressed, but related Myc family genes that are less broadly expressed are also activated in malignancy (for example, N-Myc, which is activated in neuroblastoma, and L-Myc, which is activated in lung carcinoma ; De Pinho et al., 1991) . c-Myc can be functionally deregulated by both genetic or epigenetic mechanisms, for example, by chromosomal translocation or by constitutive expression due to activation of upstreamacting growth factor receptors, respectively. Many studies have documented c-Myc overexpression in cancer. However, because deregulation rather than overexpression of Myc is sucient for oncogenic activation, the involvement of Myc in cancer may be much broader than indicated by these studies. c-Myc is crucial for cell proliferation in normal and neoplastic settings. Following mitogenic stimulation of normal quiescent cells, c-Myc is rapidly induced and remains elevated, suggesting that it is required for continuous cell growth. Although its exact role is not entirely clear, c-Myc appears to be needed at several points during the cell cycle (Evan and Littlewood, 1993) . Induction of c-Myc is sucient to drive quiescent cells into the cell cycle (Eilers et al., 1989) , while inhibition of Myc can block mitogenic signals and facilitate cell differentiation (Hanson et al., 1994; Heikkila et al., 1987; Holt et al., 1988; Sawyers et al., 1992; Sklar et al., 1991) . Associated with its ability to drive proliferation is an equally potent ability to drive apoptosis (Askew et al., 1991; Evan et al., 1992) . However, this feature is latent and only revealed in normal cells if c-Myc expression is uncoupled from survival signals mediated by cytokine and adhesion receptors (see Prendergast, this issue) .
The mechanisms through which c-Myc mediates its diverse eects on cell fate are unknown. A broad body of work argues convincingly that c-Myc is a transcription factor which activates and represses dierent target genes (Amati et al., 1998; Bouchard et al., 1998; Dang, 1999; Facchini and Penn, 1998; Henriksson and LuÈ scher, 1996; Lemaitre et al., 1996; Prendergast, 1997; Steiner et al., 1996) . However, there are a large number of studies which suggest that c-Myc has unique aspects beyond those associated with`classical' transcription factors (Lemaitre et al., 1996; Prendergast, 1997) and the identi®cation of cellular factors which interact with c-Myc in cells would provide deeper insight into other possible function(s). The C-terminal domain (CTD) of c-Myc mediates DNA binding to physiological target genes through a heterodimer complex with basic region/ helix ± loop ± helix/`leucine zipper' (b/HLH/Z) protein Max. The N-terminal domain (NTD) includes the transcription activation domain (TAD). Two short segments in the NTD termed Myc boxes 1 and 2 (MB1 and MB2) are conserved in all Myc family proteins and are crucial for all biological activities. The NTD also mediates transcriptional repression (Li et al., 1994; Philipp et al., 1994) . Both the NTD and CTD are crucial for all biological activities whereas the central portion of c-Myc is dispensable. In recent years, barriers to the identi®cation of cellular proteins which interact with c-Myc have begun to give way, providing new avenues for investigation of c-Myc function. New CTD-interacting proteins reinforce the role of this region in mediating speci®c DNA binding and suggest novel levels at which DNA binding is regulated. New NTD-binding proteins suggest links to the transcriptional regulatory machinery, including the anticipated link to complexes that contain histone acetylases, but also hint at novel connections to cell cycle regulation, chromatin remodeling, and apoptosis. Table 1 presents a list of the c-Myc-interacting proteins surveyed in this review along with their potential roles.
CTD-interacting proteins
The essential CTD spans aa 360 ± 437 in c-Myc and is comprised of the b/HLH/Z domain. In addition to Max, the proteins Nmi, YY-1, AP-2, TFII-I, BRCA1, and Miz-1 have each been implicated in interactions with this region. All these proteins have been linked to transcriptional regulation, most strongly in the cases of YY-1, AP-2, and TFII-I. Investigations of the interactions between c-Myc and these proteins have strengthened the notion that the function of the CTD is to control the access of the NTD to particular genetic loci. However, the results of several investigations have also prompted the idea that the association of c-Myc may have a reciprocal regulatory eect on the CTD-binding factors, especially in the cases of YY-1 and TFII-I. In this sense, some of the recent work introduces the idea that the CTD may also act as a domain that regulates the activity of other transcription factors, by sequestering them or preventing their interaction with other factors (such as, for example, the interaction of YY-1 with TBP or TFII-B, or the interaction of TFII-I with TBP.
Max
The identi®cation of Max, a physiological b/HLH/Z partner protein for c-Myc, was a milestone that provided the basic insight into how c-Myc recognizes DNA (reviewed in Blackwood et al., 1992b; Henriksson and LuÈ scher, 1996; Kato and Dang, 1992; Meichle et al., 1992; . The function of Max is to control the access of Myc proteins to their physiological DNA recognition sites. Max is essentially comprised of a b/HLH/Z domain and a C-terminal nuclear localization sequence. X-ray crystallographic analysis of the b/HLH/Z from this simple protein provided the ®rst glimpse of the structure of the HLH domain (Ferre-D'Amare et al., 1993) . Heterodimerization with Max is necessary for c-Myc to mediate proliferation, transformation, and apoptosis (Amati et al., 1993a,b; Mukherjee et al., 1992; . Homodimerization of Max occurs in vitro but it is unclear if homodimerization is meaningful in vivo . The DNA binding capacity of Max is subject to regulation by casein kinase II-mediated phosphorylation proximal to the basic region and by alternate splicing (Arsura et al., 1995; Berberich et al., 1992; Bousset et al., 1993; MaÈ kelaÈ et al., 1992; Prochownik and Van Antwerp, 1993; Vastrik et al., 1995) . Max is a long-lived and constitutively expressed protein whose levels are upregulated several-fold by serum growth factors in all cells examined except certain 3T3 cells (Berberich et al., 1992; Blackwood et al., 1992a; Martel et al., 1995; Shibuya et al., 1992; Wagner et al., 1992) . Examples of Max deletion have been seen in PC12 pheochromocytoma cells (Hopewell and Zi, 1995) , suggesting that other Myc partner proteins exist. Although the human Max gene lies at chromosome 14q23 where abnormalities occur in some cancers (Wagner et al., 1992) , alterations of Max do not appear to occur in malignant cells.
Max also interacts with the Mad family of b/HLH/ Z proteins which are implicated in transcriptional repression, cell growth inhibition, and dierentiation (Amati and Land, 1994; Foley et al., 1998; Hurlin et al., 1994; Schreiber-Agus and DePinho, 1998) . Mad/ Max heterodimers recognize Myc/Max E box sequences and repress transcription via Mad-dependent interactions with the corepressor protein mSin3 (Ayer et al., 1995; Schreiber-Agus et al., 1995) , which recruits histone deacetylases that remodel chromatin and suppress transcription (Hassig et al., 1997; Laherty et al., 1997) . Max and Mad arose earlier in evolution earlier than Myc. For example, homologs of Max and Mad but not of Myc can be found in C. elegans that function similarly to their human counterparts (Yuan et al., 1998) , whereas Myc has been found only as far down the evolutionary tree as Drosophila (Gallant et al., 1996) . Thus, Max stands at a crossroads between Myc and Mad proteins whose actions oppose each other in proliferation and dierentiation . Max also heterodimerizes with the b/HLH/Z protein Rox/Mnt, which is also implicated in binding to Myc/Max and Mad/ Max DNA binding sites, dierentiation, and transcriptional repression via an mSin3-dependent mechanism Meroni et al., 1997) . Max switches from Myc to Mad and probably Mnt during dierentiation (Ayer and Eisenman, 1993; Cultraro et al., 1997; Hurlin et al., 1997; Larsson et al., 1997; Meroni et al., 1997) , although Max may not be an obligate partner in all Mad complexes during dierentiation (Gupta et al., 1998; Ryan and Birnie, 1997a) . Recent investigations of Max are considered further by Luscher and Larsson in this issue.
Nmi
Nmi was identi®ed in a yeast two hybrid screen for proteins that could interact with the N-Myc HLH/Z region (Bao and Zervos, 1996) . While the function of Nmi is unknown its C-terminus is similar to an interferon-induced leucine zipper protein, IFP 35. Nmi binds to both c-Myc and N-myc in cells and to other transcription factors in yeast. It is expressed at low levels in all fetal and adult human tissues tested, except brain, and high levels are seen in certain myeloid leukemias which also express high levels of c-myc (Bao and Zervos, 1996) . The nmi gene is located at human chromosome 22q13.3, a region which is reportedly translocated in some human leukemias. A recent report in which Nmi was identi®ed as a STATbinding protein suggests a more universal role of Nmi in transcriptional regulation (Zhu et al., 1999) . Nmi does not have any intrinsic transactivation domain but binds to all STAT proteins except STAT2 and augments STAT-activated transcription by recruiting the coactivator proteins CBP/p300. It will be of interest, therefore, to determine if Nmi plays any role in recruiting coactivator proteins to N-Myc and c-Myc, although the basis for biochemical association between Nmi and CBP/p300 in the context of STATs is unclear at this point.
YY-1
The C-terminal half of c-Myc including the central domain and CTD was identi®ed in a yeast two hybrid screen for proteins that could interact with the transcription factor Yin-Yang-1 (YY-1) (Shrivastava et al., 1993) . YY-1 regulates the transcription of many genes, including possibly c-myc itself (Riggs et al., 1993) . Depending on the context, YY-1 can serve as a repressor, activator, or initiator of transcription. YY-1 associates with c-Myc but not Max and the interaction of YY-1 with c-Myc precludes Max binding (Shrivastava et al., 1993) . Additional binding determinants for YY-1 appear to be located in the biologically dispensable central region of c-Myc. In transient cotransfection assays, c-Myc inhibited both the repressor and the activator functions of YY-1, suggesting that one way c-Myc may act is by modulating the transcriptional activities of YY-1. A subsequent study provided evidence of in vivo interaction and argued that association occurred preferentially in cells expressing higher levels of cMyc (Shrivastava et al., 1996) . In addition, the results of more detailed binding experiments implied that cMyc inhibited YY-1 activity not blocking its binding to DNA but by competitively inferring with its ability to interact with the basal transcription factors TBP and/or TFII-B (Shrivastava et al., 1996) . Consistent with physiological interaction, YY-1 was shown recently to inhibit Myc/Ras cotransformation (Austen et al., 1998). However, this eect depended on DNA binding by YY-1 but not on interaction with cMyc. Therefore, YY-1 may also act indirectly to aect c-Myc activity. Indirect regulation of c-Myc by YY-1 was further supported by the ®nding that although YY-1 did not bind to the c-Myc (TAD) in vitro it was able to inhibit transactivation by a Gal4-c-MycTAD chimeric protein in transient activation assays . The link between YY-1 and c-Myc is considered further in the review by Luscher and Larsson in this issue.
AP-2
One study has implied direct and indirect interactions between the c-Myc CTD and the transcription factor AP-2 (Gaubatz et al., 1995) . (Gaubatz et al., 1995; Morriss-Kay, 1996) . While a role for AP-2 in the regulation of proliferation by c-Myc has not been reported, AP-2 expression is reported to inhibit apoptosis by c-Myc (Moser et al., 1997) . Thus, AP-2 may block binding of c-Myc/Max to target genes with critical roles in apoptosis, such as ODC (Packham and Cleveland, 1994) .
TFII-I
Interactions between c-Myc and the transcription factor TFII-I appear to be involved in transcriptional repression by c-Myc at initiator (Inr) elements which overlap the cap site in many promoters (Li et al., 1994; Roy et al., 1993a,b) . TFII-I has been shown to bind independently to two distinct promoter elements, the pyrimidine-rich Inr site as well as E-box sites which can be regulated by c-Myc or the distantly related b/HLH protein upstream stimulatory factor 1 (USF1) . The primary structure of TFII-I reveals novel features that include six directly repeated 90 residue motifs that each possess a potential helix ± loop/span-helix homology. These unique structural features suggest that TFII-I may have the capacity for multiple protein-protein and, potentially, multiple protein-DNA interactions. Consistent with this likelihood TFII-I has shown recently to stabilize and stimulate the transactivation activity of ternary complexes of the serum response factor (SRF) and the homeobox-containing protein Phox1 (Grueneberg et al., 1997) . In vitro binding studies suggest that TFII-I and USF1 act synergistically to activate transcription through both Inr and the E-box elements of the adenovirus major late promoter , which is also a target site for c-Myc . c-Myc interacts with TFII-I and binds cooperatively at both Inr and upstream E-box promoter elements in a manner similar to USF1 (Roy et al., 1993a) . However, unlike the case with USF1, c-Myc interactions at the Inr lead to an inhibition of transcription initiation by TFII-I, apparently by precluding the ability of the latter to contact TBP (Roy et al., 1993a,b) . This inhibition is selective for a TFII-Idependent (as opposed to TFIIA-dependent) initiation pathway and correlates with the prevention of complex formation between TBP, TFII-I, and the promoter (Roy et al., 1993a) . Not all genes repressed by c-Myc have Inr sequences, but for those that do the ability of c-Myc to interfere with TFII-I seems the mostly likely mechanism of action.
BRCA-1
Using the central region of the familial breast tumor suppressor BRCA1 as bait in a two hybrid screen the c-Myc CTD was identi®ed as a BRCA1-interacting protein (Wang et al., 1998) . BRCA1 associated with c-Myc in in vitro binding assays and association between endogenous proteins was documented in mammalian cells. An intact HLH region was required in c-Myc for ecient association with BRCA1 and speci®city was argued by the inability of Max to interact similarly with BRCA1. Consistent with association in cells, overexpression of BRCA1 selectively repressed c-Myc-mediated transactivation and inhibited Ras cotransformation of embryonic ®broblasts by c-Myc but not by SV40 T antigen. Thus, BRCA1 may act in part by regulating the oncogenic potential of c-Myc, providing a molecular explanation for some of the biological eects of the BRCA1 gene product (Wang et al., 1998) . A role in governing apoptosis by c-Myc might be entertained since the lethality of BRCA1 nullizygous mice can be rescued in a p53 or p21 WAF1 nullizygous background (Hakem et al., 1997) and p53 elevation can sensitize cells to the cytotoxic eects of c-Myc (Hermeking and Eick, 1994; Wagner et al., 1994) . Another possibility is suggested by studies indicating a role for BRCA1 in transcription-coupled DNA repair (Bertwistle and Ashworth, 1998; Gowen et al., 1998; Scully et al., 1997b) . Activation of BRCA1 following DNA damage (Scully et al., 1997a) might promote cell cycle arrest and/or repair in part by inhibiting cMyc/Max interaction or DNA binding. Further investigation is needed to determine how BRCA1 interaction might regulate the physiological functions of c-Myc.
Miz-1
The zinc ®nger protein Miz-1 was identi®ed in a two hybrid screen for proteins that could interact with the c-Myc CTD (Peukert et al., 1997) . Miz-1 has in addition to its zinc ®ngers a POZ domain that functions as a transcriptional repression function. Domain mapping revealed that interaction required the HLH domain of c-Myc and an amphipathic helix in the C-terminus of Miz-1. Neither Max nor USF interacted with this protein. Miz-1 binds initiator elements at the adenovirus major late and cyclin D1 promoters, each of which are genetic targets of c-Myc (Philipp et al., 1994; , and activates transcription from both promoters. Miz-1 has a potent growth arrest function. Expression of cMyc inhibits transactivation and overcomes Miz-1-induced growth arrest in manner dependent on c-Myc/ Miz-1 association and on the integrity of the POZ domain, suggesting that binding to c-Myc activates a latent repressive function of this domain. Notably, Miz-1 is a cytosolic protein whose association with cMyc mediates nuclear localization. Fusion of a nuclear localization signal to Miz-1 induces nuclear transport and impairs the ability of c-Myc to overcome Miz-1-dependent transcriptional activation and growth arrest. Although the transcriptional targets of Miz-1 are unde®ned, a possible role for Miz-1 has been recently reported as a stabilizer of Myc against ubiquitin-mediated proteolysis (Salghetti et al., 1999) .
NTD-interacting proteins
The mysteries concerning the exact function(s) of Myc are lodged in its NTD. This part of c-Myc spans *150 N-terminal residues and constitutes the second biologically essential region of c-Myc in addition to the CTD. c-Myc is unusual in that its messenger RNA encodes two polypeptide species, one of which is derived from a non-AUG translation initiation site that results in a short Nterminal extension relative to the shorter AUGinitiated species (Hann et al., 1988) . Interestingly, the longer form (which is disrupted in certain cancers (Hann et al., 1988) has dierent DNA binding properties that allow it to recognize and activate transcription from a non-E-box site , the antisense sequence of which was actually originally identi®ed as a Myc binding site in a study assessing a putative but controversial role for c-Myc in DNA replication (Iguchi-Ariga et al., 1987) . How the N-terminal extension on the NTD in¯uences the DNA binding properties of c-Myc is not understood.
The NTD includes two short sequence motifs of 520 aa that are highly conserved among Myc family proteins, termed the Myc-homology Box 1 (MB1) and Box 2 (MB2), which are located at approximately aa 42 ± 65 and 130 ± 143 in human c-Myc, respectively (aa below also refer to human c-Myc; see Figure 1 for reference). MB1 is the major site of in vivo phosphorylation events that regulate transcription and transformation and it is a hotspot for mutation in cancer (reviewed in Henriksson and LuÈ scher, 1996; Prendergast, 1997) . In particular, T58 and S62 within the MB1 region are phosphorylated in a cell cycledependent manner, possibly by certain CDKs, MAPK, and/or GSK-3b Haas et al., 1997; Lutterbach and Hann, 1994; Seth et al., 1993; Sterner et al., 1996) . S62 appears to be play a positive role since its mutation drastically reduces transforming activity Lutterbach and Hann, 1994) . In contrast, T58 appears to be a negative regulatory site which it is frequently mutated in Burkitt's lymphomas and retroviral myc genes (Bhatia et al., 1993; Henriksson et al., 1993; Lutterbach and Hann, 1994; Papas and Lautenberger, 1985; Showe et al., 1985; Yano et al., 1993) . Interestingly, T58 is also a site for glycosylation, although the functional meaning of this event is unclear . MB2 encodes the most hydrophobic part of Myc, so it is likely to be either a core organizer for the NTD fold or an interaction motif that is not constitutively exposed to a hydrophilic environment. A combination of mutagenesis and structure-function analysis has identi®ed two TADs in the NTD, one of which is located immediately upstream of MB1 (aa 1 ± 41) and the second of which is located upstream and overlapping with MB2 (aa 103 ± 144) (Prendergast, 1997) . MB1
and sequences immediately downstream (aa 42 ± 91) have little activation or repression activity, suggesting that MB1 is the key part of a regulatory or eector region which controls or is controlled by adjacent regions. Interestingly, sequences in the MB2-overlapping TAD are conserved in particular Myc family proteins in evolution (e.g. in c-Myc or N-Myc), but they diverge between dierent family members (approximately aa 100 ± 130). This suggests that some nonredundant function(s) of the Myc family is encoded by this region. An important repression element lies between MB1 and the MB2 TAD (aa 92 ± 106) and a second overlaps MB2 itself (Prendergast, 1997) . Both MB1 and MB2 are important for Myc biology but MB2 is completely essential (Brough et al., 1995; Evan et al., 1992; Li et al., 1994; Stone et al., 1987) . In recent years, as attention has shifted to the NTD in functional analysis of Myc proteins, attention has been focused on MB1 and MB2 as crucial elements for proteinprotein interaction because of their key biological roles. Two ®rst proteins to be identi®ed as candidates for NTD interaction were the transcription factor TBP and the retinoblastoma (Rb) family protein p107 (Beijersbergen et al., 1994; Gu et al., 1994; Hateboer et al., 1993) . More recently, a-tubulin and the adaptor proteins Bin1, TRRAP, Pam, MM-1, and AMY-1 have been identi®ed as NTD-binding proteins. The identi®cation and analysis of NTD-interacting proteins had been impeded by problematic biochemical aspects of c-Myc, which is dicult to express recombinantly and is so recalcitrant to isolation in its native form that its in vivo DNA binding properties were reliably documented only quite recently (Sommer et al., 1998) . Furthermore, the NTD is a strong transactivator in yeast, ruling out straightforward two hybrid screens. However, these barriers were eventually surmounted, resulting in the recent progress to identify NTDbinding proteins. One surprising theme that has emerged is that none of the proteins identi®ed to date encode`classical' transcriptional coactivator or corepressor proteins that might have been anticipated based on earlier progress on the Mad-Max system. However, given that Myc appeared later in evolution than Mad or Max, one might expect a baroque quality or at least lack of symmetry to the NTD network based on expectations from study of the CTD network. Indeed, the recent advances suggest that the NTD-based Myc network integrates transcriptional functions with other functions concerning cell cycle transit, chromatin modeling, and apoptosis or cell fate signaling.
p107
The identi®cation of p107 as an NTD-interacting protein was cued by evidence of biological parallels in how c-Myc and adenovirus E1A caused cell transformation in collaboration with activated Ras (Land et al., 1983; Ralston, 1991; Ruley, 1983) . The interactions between E1A and the retinoblastoma protein (Rb) and p300/CBP that were required for cell transformation by that oncoprotein immediately suggested that c-Myc may have similar interactions. Early evidence that c-Myc and Rb could interact in vitro (Rustgi et al., 1991) were not con®rmed in vivo, although a later study provided evidence of indirect interaction between these proteins (Adnane and Robbins, 1995) . Subsequent investigations of the Rb-related protein p107 revealed evidence of in vivo interaction with c-Myc and inhibition of its transactivating properties (Beijersbergen et al., 1994; Gu et al., 1994) . The so-called`pocket' domain of p107 binds to the Myc NTD, requiring especially the MB2 region (Hoang et al., 1995) . p107 in complex with cyclin A/CDK2 kinase has been reported to inhibit cell cycle-dependent phosphorylation of MB1 in vitro (Hoang et al., 1995) , suggesting that c-Myc could be a downstream target of p107. In addition, p107 has been reported to mediate inhibition of cMyc transactivation and transformation by p16INK4a (Haas et al., 1997) . Thus, the phosphorylation status of p107 which is achieved by the balance between p16INK4a and cyclin D/CDK4 actions may be a crucial regulatory determinant of cMyc activity in the cell cycle (Amati et al., 1998) . However, the signi®cance of c-Myc-p107 association in tumorigenesis is unclear, since there is con¯icting evidence for the antitransforming activity of p107 in transformation (Haas et al., 1997; Prendergast, 1997) as well as the ability of Burkitt's lymphomaassociated c-Myc mutants to escape inhibition by p107 in transcriptional activation assays (Hoang et al., 1995; Smith-Sorensen et al., 1996) . However, although a consensus on the role of p107 in c-Myc mediated transactivation and cell proliferation has not fully emerged, p107 seems likely to be an important regulator of c-Myc function during the cell cycle. The fact that p107 is not mutated in cancer, like Rb, suggests that loss of this regulatory function is not crucial to deregulation of c-Myc in cancer cells, however. This negative evidence as well as the lack of a role for p107 in apoptosis, another function of c-Myc, suggested that other important NTD-binding proteins should exist to control and mediate the proliferative and proapoptotic properties of c-Myc.
TBP
In vitro binding between TBP and c-Myc has been described (Hateboer et al., 1993) but in vivo con®rmation of this result has not been reported. Still, TBP interaction may have some in vivo relevance, since several c-Myc-interacting proteins have been found to interact with TBP and c-Myc has been observed to in¯uence these interactions in vitro and in vivo. The CTD-binding proteins YY-1 and TFII-I both interact tightly with TBP and through dierent domains with c-Myc (Roy et al., 1993a,b; Shrivastava et al., 1996) , although TBP was reported to bind to c-Myc relatively weakly (Roy et al., 1993a) . Notably, c-Myc blocked transcriptionally productive interactions between TBP and YY-1 or TFII-I, consistent with the possibility that c-Myc contacts TBP in some way. Lastly, the NTD-binding protein Bin1 has been observed to bind to TBP in vitro via a region which is proximal to critical determinants for cMyc binding (Elliott et al., 1999) . Further investigations are required to determine whether interaction between the c-Myc NTD and TBP are physiologically relevant or not.
a-tubulin
One line of investigation has led to the ®nding that cMyc can associate with a-tubulin and polymerized microtubules in cells (Alexandrova et al., 1995) . This ®nding was prompted by observations that c-Myc shifts its localization to the cytosol in some cells as they exit the cell cycle (Vriz et al., 1992) , along with evidence that tubulin is responsible for the cytoplasmto-nucleus translocation of certain proteins (Alexandrova et al., 1995) . c-Myc interacted with a-tubulin and microtubules in both in vitro binding experiments and in vivo immunoprecipitation and colocalization assays. The MB1-containing region from aa 48 ± 134 was implicated in mediating the interaction. While the role of tubulin interaction is undetermined at this point, the results of this study are consistent with the hypothesis that microtubules may aid in subcellular tracking of c-Myc that occurs under certain circumstances (Lemaitre et al., 1996) .
Bin1
MB1 was used in the two hybrid screen which identi®ed the adaptor protein Bin1 . MB1 was chosen as an NTD bait because it was known to be displayed on the surface of native cMyc protein (since in vivo phosphorylation occurred there); had a potentially important negative role in cancer (since it was mutated in malignant cells); and was nontransactivating in yeast. Bin1 is a nucleocytoplasmic adaptor protein which is in excess to c-Myc in cells. Although MB1 was used to identify Bin1 in yeast, the biochemical association of Bin1 with fulllength c-Myc also requires MB2 . Consistent with dependence on MB1 and MB2, Bin1 functionally associates with c-Myc in cells and selectively inhibits its oncogenic and transactivation properties in a binding domain-dependent manner (Elliott et al., 1999; Sakamuro et al., 1996) . In Ras cotransformation assays Bin1 suppressed focus formation by c-Myc and deletion of the c-Myc binding domain (MBD) relieved suppression. Transformation by E1A, HPV E7, and mutant p53, but not SV40 T antigen were also susceptible to suppression by Bin1 via an MBD-independent mechanism. Instead, Bin1 suppression required dierent domains which are dispensable to bind Myc or suppress Myc transformation. Taken together, the results suggested that Bin1 could inhibit growth mediated either by deregulation of the c-Myc or the Rb/E2F systems (Elliott et al., 1999; Sakamuro et al., 1996) . Structure-function analysis identi®ed a possible eector region, termed BAR-C, that was not involved in c-Myc binding but was indispensable to suppress Myc transformation and tumor cell growth (Elliott et al., 1999) . Bin1 selectively suppressed transactivation of arti®cial promoters responsive to Myc/Max or Gal4-Myc as well as natural Myc-regulated promoters, including those of the ODC and a-prothymosin (pT) genes. MBD was required for suppression of Myc activation of ODC not a-pT, suggesting that Bin1 may act by more than one mechanism (Elliott et al., 1999) . Consistent with this possibility, the MBD could associate with TBP in vitro and Gal4-Bin1 fusion proteins recruited a repression function unrelated to histone deacetylases in a manner independent of the MBD (Elliott et al., 1999) . A determination of the physiological role of Bin1 in transcription, if any, requires further investigation.
Bin1 has several features of a tumor suppressor. The human Bin1 gene (Wechsler-Reya et al., 1997 ) is located at chromosome 2q14 (Negorev et al., 1996) , which lies within a hotspot for deletion in metastatic prostate cancers (Cher et al., 1996) . Loss of an adaptor protein that suppresses the oncogenic properties of c-Myc may be important in prostate cancer since c-Myc deregulation is among the most frequent events in this malignancy . A recent study provided evidence of loss of heterozygosity at the Bin1 locus in 40% of genomic DNAs from matched samples of DNA from cases of normal and malignant prostate but not bladder tissue. Bin1 is missing or epigenetically altered in 450% primary breast and prostate tumors and cell lines and also in malignant melanoma (Ge et al., manuscript submitted). Reintroduction of the wild-type gene inhibits the growth of tumor cell lines lacking endogenous Bin1 but not in cells expressing wild-type Bin1; growth inhibition is due to apoptosis ; Ge et al., manuscript submitted; Elliot et al., manuscript in preparation). Similar to other tumor suppressors Bin1 is necessary for myoblast differentiation, where it acts at an early step before p21 WAF1 elevation (Mao et al., 1999; Wechsler-Reya et al., 1998) . Interestingly, during dierentiation of myoblasts, smooth muscle, and keratinocytes, Bin1 is relocalized from mainly nuclear sites to mainly cytosolic sites (Wechsler-Reya et al., 1998; GC Prendergast, unpublished observations). Bin1 interaction with c-Myc in myoblasts might provide an explanation for recent results suggesting that c-Myc blocks dierentiation in manner separate from its cell proliferative eects (Ryan and Birnie, 1997b), similar to E1A (Frisch, 1997) .
Investigations to identify the basis for Bin1 action indicate that it has a necessary role in the mechanism by which c-Myc activates apoptosis (Sakamuro et al., manuscript submitted) . In primary chick ®broblasts, where c-Myc is sucient to drive transformation or apoptosis, expression of antisense or dominant inhibitory Bin1 genes slightly enhanced cell proliferation and anchorage-independent growth but greatly reduced the susceptibility of cells to cMyc-induced apoptosis elicited by serum deprival. A requirement for Bin1 interaction in apoptosis was implied by the ®nding that overexpression of the MBD, which dominantly interferes with the c-MycBin1 interaction, rendered cells resistant to Mycinduced apoptosis (Sakamuro et al., manuscript submitted) . In a baby rat kidney (BRK) epithelial system where c-Myc can drive p53-independent apoptosis (Sakamuro et al., 1995) , inhibition of Bin1 promoted cell proliferation and stanched cell death. Notably, Bin1 inhibition masked the cytotoxic eects of Myc to a degree that was similar to Bcl-2 and that was sucient to support cell outgrowth under suboptimal growth factor conditions. Overexpression of Bin1 did not kill IMR90 human diploid ®broblasts, but did kill tumor cells lacking endogenous Bin1 where c-Myc was deregulated. The antitransforming eects of Bin1 against c-Myc in Ras cotransformation assays may be based on switching the balance of Myc signaling to a proapoptotic eector, because overexpression of the MBD appears to both promote transformation and proliferation and reduce apoptosis in cells where cMyc is overexpressed. Taken together, these results strongly support the`dual signal' model for Myc function and suggest that Bin1 is an adaptor-eector that mediates death or death sensitization signals from c-Myc (see Prendergast, this issue).
Bin1 is in excess to c-Myc in cells and also has cMyc-independent roles in cell regulation modulated by alternate splicing (Weschler-Reya et al., 1997 Elliott et al., unpublished observations) . Thus, like most adaptor proteins, Bin1 probably participates in diverse interactions in the cell. Existing evidence suggests some role for Bin1 in coordinating cell fate decisions that are made when cells exit the cell cycle (e.g. arrest in G0, commit to dierentiate, undergo apoptosis, etc.). For example, as shown above, if cells cannot exit the cell cycle due to c-Myc deregulation, then Bin1 is necessary to mediate an abortive apoptotic signal. Alternately, if c-Myc is downregulated appropriately and as a result cells are able to exit the cell cycle, then Bin1 appears to promote arrest and dierentiation (Mao et al., 1999; Wechsler-Reya et al., 1998) . Additional information supports a complex role in cells. Bin1 is subjected to extensive alternate splicing, especially in neurons (Butler et al., 1997; Ramjaun and McPherson, 1998; Ramjaun et al., 1997; Tsutsui et al., 1997; Wechsler-Reya et al., 1997) , and it is localized to the cytosol as well as the nucleus in certain cells (Butler et al., 1997; Kadlec and Pendergast, 1997; Wechsler-Reya et al., 1998) . The terminal regions of Bin1 are structurally similar to amphiphysin, a neuron-speci®c protein and paraneoplastic autoimmune antigen in breast and lung cancer (David et al., 1994; Dropcho, 1996) , and to RVS167 and RVS161, two negative regulators of the cell cycle in yeast (Bauer et al., 1993; Crouzet et al., 1991) . Amphiphysin and brain-speci®c splice forms of Bin1, also termed amphiphysin II or amphiphysin isoform, have been implicated in receptor-mediated endocytosis (David et al., 1996; Owen et al., 1998; Wigge et al., 1997) . RVS167 and RVS161 have been implicated in endocytosis and karyogamy (Brizzio et al., 1998; Munn et al., 1995) . However, nonneuronal splice forms of Bin1 are unlikely to be involved in endocytosis, because only neuronal splice forms include exons which encode clathrin-binding determinants needed for localization to endocytotic vesicles (Ramjaun and McPherson, 1998) . It is hypothesized that the endocytosis connection in neurons re¯ects the link between survival and the achievement of a dierentiated and synaptically active state in those cells, which would be associated with neurotransmitter release and hence membrane tracking. Recently, the nuclear tyrosine kinase c-Abl was shown to associate with but not to phosphorylate Bin1 in cells (Kadlec and Pendergast, 1997) . Association of c-Abl with Bin1 is mediated by its SH3 domain, which is dispensable for association with c-Myc (Elliott et al., 1999; Sakamuro et al., 1996) . How c-Abl and Bin1 in¯uences each other's actions in cell fate decisions remains to be determined. In summary, Bin1 is a nucleocytoplasmic cell fate adaptor with an important role in mediating apoptosis and possibly other cell fate decisions in¯uenced by c-Myc. Continued investigations of Bin1 may open up new vistas on Myc function.
MM-1
MM-1 (Myc Modulator-1) was identi®ed in a two hybrid screen for proteins that could interact with the entire c-Myc protein (Mori et al., 1998) . MM-1 is a nucleocytoplasmic protein that is ubiquitously expressed in normal tissues. Evidence that MM-1 interacted with c-Myc derived from extensive yeast and mammalian two-hybrid assays and in vitro GST binding assays. Deletion analyses showed that most of 
TRRAP
One of the pressing issues regarding Myc function is how transcriptional activation and repression is mediated by the NTD. In addition, the exact means by which the NTD acts to stimulate cell proliferation and malignant transformation has been obscure since the discovery of c-Myc in the 1980s. Rapid advances in the study of the Mad-Max system revealed that Mad suppressed transcription of target genes through interaction with the corepressor protein mSin3, which recruits histone deacetylases that mediate gene repression (Schreiber-Agus and DePinho, 1998) . Given the ability of c-Myc to activate transcription it was widely anticipated that c-Myc would recruit histone acetylases in some manner, but evidence of this was not forthcoming. An apparent recent breakthrough regarding this issue is the discovery of the ATM-related MB2-dependent c-Myc binding protein TRRAP (TRansformation/tRanscription-domain-Associated Protein) . TRRAP was puri®ed biochemically by using DNA-bound Gal4-Myc fusion proteins as an anity matrix and a Gal4-MycDMB2 protein lacking the MB2 region as a negative control. TRRAP is a huge protein of 4400 kD that is surprisingly devoid of notable sequence motifs with the exception of an ATM kinase-related domain in its extreme C-terminus. However, this domain lacks enzymatic activity, probably because it lacks key residues which are required for such activity in other ATM family proteins. Thus, this region may serve as a proteinprotein interaction domain, perhaps serving as an inhibitor of other ATM family interactions. By expressing sense and antisense fragments of the TRRAP cDNA, evidence was obtained that TRRAP was essential for Ras cotransformation of embryo ®broblasts by both Myc and E1A. Interestingly, TRRAP is in excess to c-Myc and also binds to the transactivation domain of E2F1, suggesting a broader role in cell growth and perhaps transcriptional regulation. A biologically active E2F1 mutant, Y411C, which cannot bind to Rb (which also binds the E2F1 transactivation domain) still interacts with TRRAP in cells, suggesting that TRRAP is an positive cofactor for both Myc and E2F transactivation activity. It will be of particular interest to determine if there is a competitive binding relationship between TRRAP and negative c-Myc NTD regulators or eectors, such as p107, Bin1, or MM-1, or in the case of E2F1, between TRRAP and Rb.
Unlike E2F1 and c-Myc, TRRAP is conserved in evolution to yeast, suggesting a more general role in cell regulation. A recent study identi®es the yeast ortholog of TRRAP, Tra1, as a component of the major transcriptional regulatory complex SAGA (Saleh et al., 1998) . This Tra1-containing complex includes histone acetyltransferases and transcription adaptors/ coactivators that in animal cells play an important role in the regulation of enhancers by altering chromatin structure (Grant et al., 1998) . While the role of Tra1 in SAGA remains to be determined, and connections between TRRAP and mammalian SAGA complexes must be con®rmed, it seems eminently likely that TRRAP may provide the long-awaited linkage between c-Myc and a boni®ed, histone acetylase-containing transcriptional complex. Continued investigations would seem likely to give fundamental insights into how c-Myc controls transcriptional activation, repression, or both, through interactions with TRRAP and probable recruitment of SAGA. At this point, the simplest hypothesis would be that the recruitment of histone acetyltransferase activity to c-Myc/Max binding sites via TRRAP would lead to proximal chromatin remodeling and the recruitment of basal transcription complexes.
Pam
A similar GST fusion technique to generate soluble cMyc NTD was used for expression screening of a phage library to obtain Pam (Protein Associated with Myc) (Guo et al., 1998) . Pam is another huge NTDbinding protein with a MW4500 kD. Through in vitro and in vivo binding assays Pam was shown to associate with c-Myc but not with N-Myc. The region implicated was aa 107 ± 154, spanning the region mentioned above where there is evolutionarily conservation within a single protein but divergence among family members (aa 100 ± 130). Thus, it is tempting to speculate that Pam may have a function that is speci®c for c-Myc. The functional relevance of Pam in Myc biology has not yet been assessed. However, a notable feature of Pam is the two regions it contains which are similar to RCC1, the nuclear regulator of the cell cycle and chromatin condensation. RCC1 is a guanine nucleotide exchange protein (GEF) for the small nuclear Ras superfamily protein Ran, which regulates trac through the nuclear pore. It will be interesting to explore possible roles for the Myc/Pam complex in chromatin modeling, given the role of RCC1 in controlling the onset of chromosome condensation (Ohtsubo et al., 1989) , or in RNA transport, since Ran mediates this process and c-Myc also regulates gene expression at some nuclear posttranscriptional level other than splicing (Prendergast and Cole, 1989 
AMY-1
Another novel protein that interacts with the c-Myc NTD is Amy-1 (Associate of c-MYc-1) . Amy-1 is a small protein of *11 kD which physically associates with c-Myc in cells via an MB2-containing determinant within aa 48 ± 158. Association of Amy-1 with c-Myc stimulates its E-box-dependent transactivation activity. Amy-1 appears to be subjected to alternate splicing since two types of messages encoding so-called Amy-1S (short) and Amy-1L (long) are expressed, both of which have the same open reading frame and only vary in the amount of 5'-noncoding sequence included. Amy-1 expression is ubiquitous but regulated in a cell cycle-dependent manner, with its highest peak in early S phase. Amy-1 presents another example of a cytosolic Myc-binding protein which translocates into the nucleus at times of increased c-Myc expression and commitment to enter S phase. Interestingly, Amy-1 lacking Myc-binding activity does not translocate into the nucleus appropriately, suggesting that its movement is dependent upon association with Myc. Following S phase, Amy-1 returns to the cytoplasm. Binding experiments suggest that Amy-1 only binds certain phosphorylated forms of c-Myc that are cell cycle controlled. It is hypothesized that Amy-1 is recruited into the nucleus when c-Myc transactivates S phasespeci®c target genes. As mentioned above, the Myc CTD-binding protein Miz-1 also exclusively exists in the cytoplasm and c-Myc association mediates nuclear import of Miz-1. Therefore, it may be interesting to see if there is any crosstalk between Amy-1 and Miz-1 in terms of cell localization and Myc transcriptional regulation.
Closing perspective
The role of c-Myc in transcriptional regulation is strengthened by the identi®cation of several boni®ed transcription factors (YY-1, TFII-I, AP-2) and adaptor proteins found in transcriptional regulatory complexes (TRRAP in SAGA) as factors that functionally interact with the CTD and NTD of cMyc. However, as the number of proteins with which c-Myc interacts begins to enlarge, it appears that the centrality of c-Myc in cell fate regulation re¯ects dynamic interactions with a wide number of complex regulatory and eector proteins. Analyses of NTD binding proteins argue that the primary level of complexity to be understood is at the NTD network rather than the CTD network, which is responsible for DNA recognition. Thus, the CTD network involves the Mad-Mnt/Rox and Max interactions which oppose Myc function by recruiting mSin3 recruitment and closing chromatin via histone deacetylase action, whereas the NTD network involves a host of proteins, at least one of which is connected directly to a complex containing histone acetylases. Given the ability of several NTD network proteins to modulate transcription, it is tempting to speculate that activation of dierent classes of target requires global regulation mediated by TRRAP and then speci®c regulation that is dictated by accessory NTD-binding proteins such as p107, Bin1, MM-1, and Amy-1, which may coordinate targets with cell cycle, apoptosis, etc. In this sense, the novel NTD network proteins may provide valuable tools to sort out the physiological roles of the growing number of cellular genes (currently 430) which have been identi®ed as genetic targets of c-Myc activity (Dang, 1999) . While Myc is certainly a bona ®de transcription factor, its functions appear to extend beyond that of a classical transcription factor; the identi®cation of binding proteins such as Bin1 and Pam suggest unique signaling roles for c-Myc, related to cell fate determination and possibly chromatin modulation or nuclear tracking actions. Analysis of the NTD network in particular seems likely to breakdown the enigmatic properties of Myc, possibly providing novel insights into basic cell processes as well as oering new avenues for intervention in hyperproliferative diseases where c-Myc is involved, most notably in cancer.
